Interventional, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study Part Investigating the Safety, Tolerability, and Pharmacokinetic and -Dynamic Properties of Lu AF90103 and a Double-Blind, Cross-Over Study Part Investigating the Safety Profile After Infusion of Lu AF90103 at Two Rates to Healthy Men
Latest Information Update: 21 Mar 2023
At a glance
- Drugs Lu AF90103 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Lundbeck A/S
Most Recent Events
- 16 Dec 2022 Status changed from recruiting to discontinued.
- 17 Jun 2022 Planned End Date changed from 23 Aug 2022 to 30 Nov 2022.
- 17 Jun 2022 Planned primary completion date changed from 1 Apr 2022 to 30 Nov 2022.